Chemomab Revenue and Competitors
Estimated Revenue & Valuation
- Chemomab's estimated annual revenue is currently $8M per year.
- Chemomab's estimated revenue per employee is $201,000
Employee Data
- Chemomab has 40 Employees.
Chemomab's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chief Financial Officer | Reveal Email/Phone |
2 | Consulting VP, Investor & Public Relations, Strategic Communications | Reveal Email/Phone |
3 | Clinical Trial Manager | Reveal Email/Phone |
4 | Executive Office Administrator | Reveal Email/Phone |
5 | Project Leader | Reveal Email/Phone |
Chemomab Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $53.7M | 267 | 16% | N/A | N/A |
#2 | $53.1M | 264 | 21% | N/A | N/A |
#3 | $69.1M | 344 | 26% | N/A | N/A |
#4 | $22.1M | 110 | -10% | N/A | N/A |
#5 | $151.8M | 755 | 11% | N/A | N/A |
#6 | $63.9M | 318 | 13% | N/A | N/A |
#7 | $29.9M | 149 | 13% | N/A | N/A |
#8 | $1.7M | 17 | -6% | $114.3M | N/A |
#9 | $6.8M | 34 | -6% | N/A | N/A |
#10 | $12.5M | 62 | -9% | N/A | N/A |
What Is Chemomab?
Chemomab Ltd. is a clinical-stage biotech company, focusing on discovery and development of innovative therapeutics for fibrosis-related diseases. Chemomab is making great strides with its novel CM-101 proprietary platform, which hinders the fundamental function of the soluble chemokine CCL24 as a regulator of major inflammatory and fibrotic pathways in multiple fibrosis-related disorders. CM-101, the company's lead clinical candidate, is a first-in-class monoclonal antibody that targets CCL24. Chemomab has shown that CM-101 interferes with the underlying biology of fibrosis using a novel and differentiated mechanism of action. Chemomab is actively advancing CM-101 into phase 2 studies to treat patients with liver fibrosis (Primary Sclerosing Cholangitis and Non-alcoholic Steatohepatitis) and patients suffering from skin and lung fibrosis (Systemic Sclerosis).
keywords:N/A
N/A
Total Funding
40
Number of Employees
$8M
Revenue (est)
N/A
Employee Growth %
N/A
Valuation
N/A
Accelerator
Chemomab News
Chemomab Therapeutics Ltd. engages in the research and development of biological drugs for the treatment of inflammatory and fibrotic diseases.
CHEMOMAB THERAPEUTICS LTD. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K) ... and the related...
Chemomab is a clinical-stage biotechnology company focusing on the discovery and development of innovative therapeutics for fibrotic and...
Other Companies in
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $6.4M | 40 | -9% | N/A |
#2 | $8.2M | 40 | 5% | $200M |
#3 | $10.4M | 40 | -7% | N/A |
#4 | $10M | 40 | -9% | N/A |
#5 | $8M | 40 | 5% | N/A |